Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes

Original Research

¹Research and Clinic Divisions, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
²Department of Medicine, Brigham and Women′s Hospital, Harvard Medical School, Boston, Massachusetts
³Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland
⁴Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
⁵Renal Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
⁶Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
⁷Division of Nephrology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts

Corresponding author: Andrzej S. Krolewski, andrzej.krolewski{at}joslin.harvard.edu.

Diabetes Care 2012 Nov; 35(11): 2311-2316. https://doi.org/10.2337/dc11-2220

Article Figures & Tables

Download figure
Open in new tab
Download powerpoint
Figure 1
Ten-year cumulative risks of ESRD in patients with T1D were calculated by actuarial methods according to CKD stages determined jointly by eGFRcrea and eGFRcyst. The pattern of differences was similar in the Joslin and FinnDiane cohorts of T1D, so the cohorts were pooled as a single cohort. The percentages on the boxes are 10-year cumulative risks of ESRD. : Concordant CKDcyst and CKDcrea stages. : CKDcyst stage is higher (eGFR is lower) than the CKDcrea stage. : CKDcyst stage is lower (eGFR is higher) than the CKDcrea stage.